2Greipp P R.Eastern cooperative oncology group E1A00:phase Ⅲ randomized study of dexamethasone with or without thalidomide in patients with newly diagnosed multiple myeloma[J].Clin Adv Hematol Oncol,2003,1 (3):188-189. 被引量：1
3Brocke-Heidrich K,Kretz schmar A K,Pfeifer G,et al.Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation[J].Blood,2004,103 (1):242-251. 被引量：1
4Hats H,Xiao H,Petrucci M T,et al.Interleukin-6 gene expression in multiple myeloma:a characteristic of immature tumor cells[J].Blood,1993,81 (12):3357 -3364. 被引量：1
5Szczepek A J,Belch A R,Pilarski L M.Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma:potential for autocrine and paracrine networks[J].Exp Hematol,2001,29(9):1076-1081. 被引量：1
1Richardson PG, Hideshima T, Anderson KC. Bortezomib ( PS2341 ) : a novel, first2in2class p roteasome inhibitor for the treatmentof multip le myeloma and other cancers. Cancer Control ,2003,10(5) :361-369. 被引量：1
2Shao XD,Wu KC,Hao ZM. The potent inhibitory effects of cisapride,a specific blocker for human ether-a-go-go-related gene(HERG) channel,on gastric cancer cells[J].Cancer Biology and Therapy,2005,(03):295-301. 被引量：1
3Doss DS,Swift R,Colean K. Expanding role of bortezomib in multiple myeloma:nursing implications[J].Cancer Nursing,2008,(30):239-245. 被引量：1
